Douleur et Analgésie

, Volume 23, Issue 3, pp 166–174

Nouveautés et perspectives dans le traitement de la migraine

Revue De La Littérature / Literature Review
  • 92 Downloads

Résumé

Les nouveautés et les perspectives du traitement de la migraine concernent le traitement de la crise migraineuse, le traitement prophylactique de la migraine épisodique et le traitement prophylactique de la migraine chronique. Les avancées les plus prometteuses concernent des approches pharmacologiques et des approches instrumentales. Pour le traitement de la crise migraineuse, ces avancées concernent les antagonistes des récepteurs du CGRP, les agonistes des récepteurs 5-HT1F et la stimulation magnétique transcrânienne. Pour le traitement prophylactique de la migraine épisodique, ces avancées concernent les inhibiteurs de la dépression corticale envahissante et la fermeture chirurgicale du foramen ovale perméable. Enfin, pour le traitement de la migraine chronique, ces avancées concernent la toxine botulinique de type A et la neuromodulation par stimulation du nerf grand occipital.

Mots clés

Migraine sans aura Migraine avec aura Abus médicamenteux Migraine chronique Traitement 

New developments and prospects in the treatment of migraine

Abstract

Innovations and prospects for the migraine treatment relate to the treatment of the migraine attack, the prophylactic treatment of episodic migraine and the prophylactic treatment of chronic migraine. These innovations are pharmacological approaches and instrumental approaches. For the treatment of the migraine attack, these innovations relate to CGRP antagonists, 5-HT1F agonists and transcranial magnetic stimulation. For the prophylactic treatment of the episodic migraine, these innovations relate to cortical spreading depression inhibitors and persistent foramen ovale closure. Lastly, for the treatment of the chronic migraine, these projections relate to botulinum toxin type A and the neuromodulation by greater occipital nerve stimulation.

Keywords

Migraine without aura Migraine with aura Medication overuse Chronic migraine Treatment 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Références

  1. 1.
    Aurora SK, Dodick DW, Turkel CC, et al (2010) Onabotulinumtoxin A for treatment of chronic migraine: results from the double-blind, randomized, placebo controlled phase of the PREEMPT-1 trial. Cephalalgia, Epub, DOI: 10.1177/0333102410364676Google Scholar
  2. 2.
    Ayata C, Jin H, Kudo C, et al (2006) Suppression of cortical spreading depression in migraine prophylaxis. Ann Neurol 59:652–61CrossRefPubMedGoogle Scholar
  3. 3.
    Bartsch T, Goadsby PJ (2002) Stimulation of the greater occipital nerve induces increased central excitability of dural afferent input. Brain 125:1496–509CrossRefPubMedGoogle Scholar
  4. 4.
    Bigal ME, Lipton RB (2006) Modifiable risk factors for migraine progression. Headache 46:1334–43CrossRefPubMedGoogle Scholar
  5. 5.
    Bigal ME, Lipton RB (2008) Concepts and mechanisms of migraine chronification. Headache 48:7–15CrossRefPubMedGoogle Scholar
  6. 6.
    Clarke BM, Upton AR, Kamath MV, et al (2006) Transcranial magnetic stimulation for migraine: clinical effects. J Headache Pain 7:341–46CrossRefPubMedGoogle Scholar
  7. 7.
    Connor KM, Shapiro RE, Diener HC, et al (2009) Randomized, controlled trial of telcagepant for the acute treatment of migraine. Neurology 73:970–77CrossRefPubMedGoogle Scholar
  8. 8.
    Damodaram S, Thalakoti S, Freeman SE, et al (2009) Tonabersat inhibits trigeminal ganglion neuronal-satellite glial cell signaling. Headache 49:5–20CrossRefPubMedGoogle Scholar
  9. 9.
    Diener HC (2010) Single-pulse transcranial magnetic stimulation: a new way to treat migraine attacks with aura. Lancet Neurol 9:335–7CrossRefPubMedGoogle Scholar
  10. 10.
    Diener HC, Bussone G, Van Oene JC, et al (2007) Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study. Cephalalgia 27:814–23CrossRefPubMedGoogle Scholar
  11. 11.
    Diener HC, Dodick DW, Goadsby PJ, et al (2009) Utility of topiramate for the treatment of patients with chronic migraine in the presence or absence of acute medication overuse. Cephalalgia 29:1021–7CrossRefPubMedGoogle Scholar
  12. 12.
    Dodick DW, Aurora SK, Turkel CC, et al (2009) Botulinum neurotoxin type A for treatment of chronic migraine: the double-blind phase of the PREEMPT clinical program [abstract]. Cephalalgia 29(suppl 1):34Google Scholar
  13. 13.
    Dodick DW, Turkel CC, Degryse RE, et al (2010) Onabotulinum-toxin A for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia [Epub ahead of print]Google Scholar
  14. 14.
    Dowson A, Mullen MJ, Peatfield R, et al (2008) Migraine intervention with STARFlex Technology (MIST) trial. A prospective, multicenter, double-blind, sham-controlled trial to evaluate the effectiveness of patent foramen ovale closure with STARFlex septal repair implant to resolve refractory migraine headache. Circulation 117:1397–404CrossRefPubMedGoogle Scholar
  15. 15.
    Evers S, Marziniak M (2010) Clinical features, pathophysiology, and treatment of medication-overuse headache. Lancet Neurol 9:391–401CrossRefPubMedGoogle Scholar
  16. 16.
    Garg P, Servoss SJ, Wu JC, et al (2010) Lack of association between migraine headache and patent foramen ovale: results of case-control study. Circulation 121:1406–12CrossRefPubMedGoogle Scholar
  17. 17.
    Gazerani P, Staahl C, Drewes AM, Arendt-Nielsen L (2006) The effects of botulinum toxin type A on capsaicin-evoked pain, flare, and secondary hyperalgesia in an experimental human model of trigeminal sensitization. Pain 122:315–25CrossRefPubMedGoogle Scholar
  18. 18.
    Gazerani P, Pedersen NS, Staahl C, et al (2009) Subcutaneous botulinum toxin type A reduces capsaicin-induced trigeminal pain and vasomotor reactions in human skin. Pain 141:60–9CrossRefPubMedGoogle Scholar
  19. 19.
    Goadsby PJ (2008) Calcitonin gene-related peptide (CGRP) antagonists and migraine. Is this a new era? Neurology 70:1300–1CrossRefPubMedGoogle Scholar
  20. 20.
    Goadsby PJ, Dodick DW, Saper JR, Silberstein SD (2009) Occipital nerve stimulation (ONS) for treatment of intractable chronic migraine (ONSTIM) [abstract]. Cephalalgia 29:133Google Scholar
  21. 21.
    Goadsby PJ, Ferrari MD, Csanyi A, et al (2009) Randomized, double-blind, placebo-controlled, proof of concept study of the cortical spreading depression inhibiting agent tonabersat in migraine prophylaxis. Cephalalgia 29:742–50CrossRefPubMedGoogle Scholar
  22. 22.
    Hagen K, Albresten C, Vilming SF, et al (2009) Management of medication overuse headache: 1-year randomized multicentre open-label trial. Cephalalgia 29:221–32CrossRefPubMedGoogle Scholar
  23. 23.
    Hauge AW, Asghar MS, Schytz HW, et al (2009) Effects of tonabersat on migraine with aura: a randomised, doubleblind, placebo-controlled crossover study. Lancet Neurol 8:718–23CrossRefPubMedGoogle Scholar
  24. 24.
    Headache Classification Committee, Olesen J, Bousser MG, et al (2006) New appendix criteria open for a broader concept of chronic migraine. Cephalalgia 26:742–6CrossRefPubMedGoogle Scholar
  25. 25.
    Headache Classification Committee of the International Headache Society (2004) The International Classification of Headache Disorders (2nd ed). Cephalalgia 24(suppl 1):1–160Google Scholar
  26. 26.
    Ho TW, Ferrari MD, Dodick DW, et al (2008) Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial. Lancet 372:2115–23CrossRefPubMedGoogle Scholar
  27. 27.
    Ho TW, Mannix LK, Fan X, et al (2008) Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine. Neurology 70:1304–12CrossRefPubMedGoogle Scholar
  28. 28.
    Holland PR, Schembri CT, Fredrick JP, Goadsby PJ (2009) Transcranial magnetic stimulation for the treatment of migraine aura. Neurology 72(suppl 3):A250 (abstr IN4-1.005)Google Scholar
  29. 29.
    Lauritzen M (1994) Pathophysiology of the migraine aura. The spreading depression theory. Brain 117:199–210CrossRefPubMedGoogle Scholar
  30. 30.
    Le Doaré K, Akerman S, Holland PR, et al (2006) Occipital afferent activation of second order neurons in the trigeminocervical complex in rat. Neurosci Lett 403:73–7CrossRefPubMedGoogle Scholar
  31. 31.
    Lipton RB, Bigal ME, Diamond M, et al (2007) Migraine prevalence, disease burden, and the need for preventive therapy. Neurology 68:343–9CrossRefPubMedGoogle Scholar
  32. 32.
    Lipton RB, Dodick DW, Silberstein SD, et al (2010) Single-pulse transcranial magnetic stimulation for acute treatment with aura: a randomized double-blind, parallel-group, sham-controlled trial. Lancet Neurol 9:373–80CrossRefPubMedGoogle Scholar
  33. 33.
    Lipton RB, Goadsby PJ, Cady RK, et al (2009) PRISM study: occipital nerve stimulation for treatment-refractory migraine [abstract]. Cephalalgia 29(suppl 1):30Google Scholar
  34. 34.
    Matharu MS, Bartsch T, Ward N, et al (2004) Central neuromodulation in chronic migraine patients with suboccipital stimulators: a PET study. Brain 127:220–30CrossRefPubMedGoogle Scholar
  35. 35.
    Mohammad TM, Hughes G, Nkrumah M, et al (2006) Self-administered transcranial magnetic stimulation (TMS) during the aura phase improved and aborts headache. Headache 46:857Google Scholar
  36. 36.
    Olesen J, Diener HC, Husstedt IW, et al (2004) Calcitonin generelated peptide (CGRP) receptor antagonist BIBN 4096 BS is effective in the treatment of migraine attacks. N Engl J Med 350:1104–10CrossRefPubMedGoogle Scholar
  37. 37.
    Paone DV, Shaw AW, Nguyen DN, et al (2007) Potent, orally bioavailable calcitonin gene-related peptide receptor antagonists for the treatment of migraine: discovery of N-[(3R,6S)-6-(2,3-difluorophenyl)-2-oxo-1-(2,2,2-trifluoroethyl)azepan-3-yl]-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxamide (MK-0974). J Med Chem 50:5564–7CrossRefPubMedGoogle Scholar
  38. 38.
    Petersen KA, Birk S, Lassen LH, et al (2005) The CGRP-antagonist, BIBN4096BS does not affect cerebral or systemic haemodynamics in healthy volunteers. Cephalalgia 25:139–47CrossRefPubMedGoogle Scholar
  39. 39.
    Pilgrim A, Dussault B, Rupniak N, White J (2009) COL-144, an orally bioavailable selective 5-HT1F receptor agonist for acute migraine therapy [abstract]. Cephalalgia 29(suppl 1):24Google Scholar
  40. 40.
    Reuter U, Pilgrim A, Diener HC, et al (2009) COL-144, a selective 5-HT1F agonist for the treatment of migraine attacks [abstract]. Cephalalgia 29:122Google Scholar
  41. 41.
    Ruppel PL (2006) Statistical report: Neuralieve protocol NL-2006-002-effectiveness of masking of a sham device compared to sTMS in asymptomatic migraineurs with and without a history of visual aura (Aug 7, 2006). Kalamazoo: Innovative AnalyticsGoogle Scholar
  42. 42.
    Salvatore CA, Hershey JC, Corcoran HA, et al (2008) Pharmacological characterization of MK-0974 [N-[(3R,6S)-6-(2,3-difluorophenyl)-2-oxo-1-(2,2,2-trifluoroethyl)azepan-3-yl]-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxamide], a potent and orally active calcitonin gene-related peptide receptor antagonist for the treatment of migraine. J Pharmacol Exp Ther 324:416–21CrossRefPubMedGoogle Scholar
  43. 43.
    Schoonman GG, van der Grond J, Kortmann C, et al (2008) Migraine headache is not associated with cerebral or meningeal vasodilatation-a 3T magnetic resonance angiography study. Brain 131:2192–200CrossRefPubMedGoogle Scholar
  44. 44.
    Shuhendler AJ, Lee S, Siu M, et al (2009) Efficacy of botulinum toxin type A for the prophylaxis of episodic migraine headaches: a meta-analysis of randomized, double-blind, placebo-controlled trials. Pharmacotherapy 29:784–91CrossRefPubMedGoogle Scholar
  45. 45.
    Silberstein S, Blumenfeld AM, Cady RK, et al (2009) Botulinum neurotoxin type A for treatment of chronic migraine: analysis of the PREEMPT chronic migraine subgroup with baseline acute headache medication overuse [abstract]. Cephalalgia 29(suppl 1):31Google Scholar
  46. 46.
    Silberstein SD, Lipton RB, Dodick DW, et al (2007) Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trial. Headache 47:170–80CrossRefPubMedGoogle Scholar
  47. 47.
    Sixit ML, Messlinger K, Fisher JM (2009) Calcitonin generelated peptide receptor antagonist olcegepant acts in spinal trigeminal nucleus. Brain 132:3134–41CrossRefGoogle Scholar
  48. 48.
    Tepper SJ, Cleves C (2009) Telcagepant, a calcitonin gene-related peptide antagonist for the treatment of migraine. Curr Opin Investig Drugs 10:711–20PubMedGoogle Scholar
  49. 49.
    Upton A, Clarke B, Castellanos C (2005) Transcranial magnetic stimulation (TMS) for migraine: clinical effect. Can J Neurol Sci 32(suppl 1):S71Google Scholar
  50. 50.
    Zeeberg P, Olesen J, Jensen R (2006) Probable medicationoveruse headache. The effect of a 2-month drug-free period. Neurology 66:1894–8CrossRefPubMedGoogle Scholar

Copyright information

© Médecine et Hygiène et Springer-Verlag France 2010

Authors and Affiliations

  1. 1.Département d’évaluation et traitement de la douleur, médecine palliative, pôle neurosciences cliniques du CHU de Nicehôpital PasteurNiceFrance

Personalised recommendations